Polymyositis is a rare debilitating condition characterized by chronic inflammation and muscle weakness. Standard treatments\ninclude corticosteroids and immunosuppressants; however, resistance to these regimens may develop. Intravenous immunoglobulins\n(IVIg) are thus recommended for patients with drug-resistant polymyositis. The patient presented a resistant polymyositis with\nseveremuscle weakness, increasing dysphagia, and significant loss in weight. Subcutaneous immunoglobulins (SCIg) were initiated\nafter failure of steroids and immunosuppressive drugs. SCIg was given twice per week (2 then 1.3 g/kg/month). Clinical recovery\nwas observed within 2 months after the SCIg initiation. After several injections, the patient showed a progressive improvement in\nmuscle strength. Serum creatine kinase activity decreased to normal levels, and dysphagia was resolved. The SC injections were\ngenerally well tolerated and good patient satisfaction was reported. This promising observation suggests that SCIg may be useful\nin active and refractory polymyositis.
Loading....